Volume 80, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


We reviewed the antibiotic susceptibility patterns of all isolates of in Ontario, Canada from January 2002 to December 2007. We identified a total of 381 unique cases over the 5-year period (50–73 cases per year). Of the 381 cases, 171 were female, 164 were male, and no gender was identified for 33 cases. Age of the patients ranged from less than 1 to 102 years of age (median age of 20 years). Although resistance patterns for ampicillin, trimethoprim-sulfamethoxazole, third generation cephalosporins (cefotaxime until May 2005 and ceftriaxone from June 2005 to present), and chloramphenicol remained stable, nalidixic acid resistance rose sharply between 2003 and 2005 and has remained at approximately 80% of isolates since 2005. The significant and sustained increase in nalidixic acid-resistant suggests that ciprofloxacin should no longer be used as the drug of choice for the empiric treatment of typhoid fever in Ontario.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Statistics Canada, 2006 Census. Available at: http://www.fin.gov.on.ca/english/economy/demographics/census/cenhi06-7.html. Accessed April 11, 2008.
  2. Rowe B, Ward LR, Threlfall EJ, 1997. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 24 (Suppl 1): S106–S109.
    [Google Scholar]
  3. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S, 1999. Ciprofloxacin-resistant Salmonelle typhi and treatment failure. Lancet 353 : 1590–1591.
    [Google Scholar]
  4. Slinger R, Desjardins M, McCarthy AE, Ramotar K, Jessamine P, Guibord C, Toye B, 2004. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 4 : 36.
    [Google Scholar]
  5. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P, 1999. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 37 : 3572–3577.
    [Google Scholar]
  6. NCCLS, 2003. Performance standards for antimicrobial susceptibility testing: Thirteenth informational supplement. NCCLS document M100-S13 (M7). Wayne, PA: NCCLS.
  7. Crump JA, Barrett TJ, Nelson JT, Angulo FJ, 2003. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotypeTyphi and for non-Typhi Salmonellae. Clin Infect Dis 37 : 75–81.
    [Google Scholar]
  8. Clinical Laboratory and Standards Institute, 2007. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. CLSI document M100-S17. Wayne, PA: CLSI.
  9. Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, Ackers M, Calugar A, Mintz ED, 2004. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 39 : 186–191.
    [Google Scholar]
  10. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh do G, Ali M, Shin S, Wain J, Page AL, Albert MJ, Farrar J, Abu-Elyazeed R, Pang T, Galindo CM, von Seidlein L, Clemens JD; Domi Typhoid Study Group, 2008. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 86 : 260–268.
    [Google Scholar]

Data & Media loading...

  • Received : 30 Oct 2008
  • Accepted : 03 Feb 2009
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error